2024
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactREPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023): 1912–1926: Predicting chronic postsurgical pain: current evidence anda novel program to develop predictive biomarker signatures
Sluka K, Wager T, Sutherland S, Labosky P, Balach T, Bayman E, Berardi G, Brummett C, Burns J, Buvanendran A, Caffo B, Calhoun V, Clauw D, Chang A, Coffey C, Dailey D, Ecklund D, Fiehn O, Fisch K, Frey Law L, Harris R, Harte S, Howard T, Jacobs J, Jacobs J, Jepsen K, Johnston N, Langefeld C, Laurent L, Lenzi R, Lindquist M, Lokshin A, Kahn A, McCarthy R, Olivier M, Porter L, Qian W, Sankar C, Satterlee J, Swensen A, Vance C, Waljee J, Wandner L, Williams D, Wixson R, Zhou X. REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023): 1912–1926: Predicting chronic postsurgical pain: current evidence anda novel program to develop predictive biomarker signatures. Ból 2024, 25: 1-19. DOI: 10.5604/01.3001.0054.4396.Peer-Reviewed Original ResearchChronic painPain SignatureDevelopment of chronic painChronic postsurgical painChronification of painEvaluate candidate biomarkersAt-risk patientsInvestigation of biomarkersPredictive biomarker signaturesPostsurgical painTreat other diseasesBiological treatment targetPainCandidate biomarkersNovel biomarkersTreatment targetOther diseasesPhenotypic expressionBiomarker signaturesBiomarkersEarly interventionNational InstituteInitial findingsBiological pathwaysSurgery
2016
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. New England Journal Of Medicine 2016, 375: 23-34. PMID: 27406347, PMCID: PMC5259561, DOI: 10.1056/nejmoa1513749.Peer-Reviewed Original ResearchConceptsPathological complete responseHuman epidermal growth factor receptor 2Triple-negative breast cancerStandard therapyComplete responseBreast cancerBiomarker subtypesExperimental regimensEpidermal growth factor receptor 2I-SPY 2Triple-negative populationCompletion of chemotherapyPrimary end pointPhase 3 trialStandard neoadjuvant chemotherapyGrowth factor receptor 2HER2-negative tumorsAdaptive randomizationBiomarker signaturesTumor volume changesFactor receptor 2Phase 2Carboplatin groupNeoadjuvant trialsNeoadjuvant chemotherapyAdaptive Randomization of Neratinib in Early Breast Cancer
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal Of Medicine 2016, 375: 11-22. PMID: 27406346, PMCID: PMC5259558, DOI: 10.1056/nejmoa1513750.Peer-Reviewed Original ResearchConceptsPathological complete responseComplete responseBreast cancerNeoadjuvant therapyStandard chemotherapyHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusBiomarker signaturesSerial magnetic resonance imagingI-SPY 2 TRIALTyrosine kinase inhibitor neratinibClinical stage IIPrimary end pointHormone receptor statusPhase 2 trialPhase 3 trialStandard neoadjuvant chemotherapyEarly breast cancerMultiple new agentsAdaptive randomizationNegative breast cancerConfirmatory phase 3 trialPhase 3 testingExperimental groupMagnetic resonance imaging
2015
Prediction of colorectal cancer diagnosis based on circulating plasma proteins
Surinova S, Choi M, Tao S, Schüffler PJ, Chang CY, Clough T, Vysloužil K, Khoylou M, Srovnal J, Liu Y, Matondo M, Hüttenhain R, Weisser H, Buhmann JM, Hajdúch M, Brenner H, Vitek O, Aebersold R. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Molecular Medicine 2015, 7: 1166-1178. PMID: 26253081, PMCID: PMC4568950, DOI: 10.15252/emmm.201404873.Peer-Reviewed Original ResearchConceptsColorectal cancer diagnosisBlood-based markersColorectal cancer detectionPatient's systemic circulationColorectal cancerSystemic circulationIndependent cohortCritical clinical needNon-invasive detectionDiagnostic valueClinical needTissue epitheliumCancer diagnosisPlasma samplesBiomarker signaturesPlasma proteinsBlood plasmaProtein biomarkersCancer detectionCandidate glycoproteinsClinical datasetsMass spectrometry-based approachCohortCancerDiagnosisMemory, executive, and multidomain subtle cognitive impairment
Toledo J, Bjerke M, Chen K, Rozycki M, Jack C, Weiner M, Arnold S, Reiman E, Davatzikos C, Shaw L, Trojanowski J, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Leon S, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Memory, executive, and multidomain subtle cognitive impairment. Neurology 2015, 85: 144-153. PMID: 26085606, PMCID: PMC4515043, DOI: 10.1212/wnl.0000000000001738.Peer-Reviewed Original ResearchConceptsCognitive impairmentAlzheimer's Disease Neuroimaging InitiativeDisease Neuroimaging InitiativeCSF Alzheimer's disease biomarkersDifferent clinical prognosesBiomarker signaturesAlzheimer's disease biomarkersCognitive impairment groupSubtle cognitive impairmentMemory complaint groupBrain atrophySingle ROISCI groupCN subjectsClinical prognosisHealthy controlsAtrophy patternsDementia stagesNeuroimaging biomarkersImpairment groupClinical cutoffComplaint groupPattern-based analysisADNI participantsSMC group
2013
A Peripheral Blood Biomarker Signature Potentially Identifies Smokers with Interstitial Lung Abnormalities
Patel A, Doyle T, Liu Y, Hatabu H, Hatabu M, Okajima Y, Risquez C, Shi Y, Osorio J, Golzarri M, Lederer J, El-Chemaly S, Pinto-Plata V, Celli B, Hunninghake G, Washko G, Sciurba F, Kaminski N, Leader J, Siegfried J, Weissfeld J, Rosas I. A Peripheral Blood Biomarker Signature Potentially Identifies Smokers with Interstitial Lung Abnormalities. CHEST Journal 2013, 144: 1029a-1029b. DOI: 10.1378/chest.1778676.Peer-Reviewed Original Research
2007
23: Chronic nitric oxide inhibition in a rat model of preeclampsia (PE) leads to urinary proteomic biomarker signatures similar to humans
Buhimschi I, Zhao G, Ravishankar V, Bahtiyar M, Saade G, Buhimschi C. 23: Chronic nitric oxide inhibition in a rat model of preeclampsia (PE) leads to urinary proteomic biomarker signatures similar to humans. American Journal Of Obstetrics And Gynecology 2007, 197: s11. DOI: 10.1016/j.ajog.2007.10.026.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply